Kiniksa Pharmaceuticals International (KNSA) Operating Expenses (2017 - 2026)

Kiniksa Pharmaceuticals International has reported Operating Expenses for 10 years, with the latest figure at $185.0 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Expenses rose 48.58% year-over-year to $185.0 million; the trailing twelve-month figure through Mar 2026 stood at $660.8 million (up 32.97% YoY), and the FY2025 full-year result was $600.3 million, up 28.04% from the prior year.
• Operating Expenses for Q1 2026 stood at $185.0 million, up from $182.4 million in the prior quarter.
• The five-year high for Operating Expenses was $185.0 million in Q1 2026, with the low at $46.3 million in Q2 2022.
• Historically, Operating Expenses has averaged $103.5 million across 5 years, with a median of $96.4 million in 2024.
• Annual changes were most pronounced in 2022 — Operating Expenses retreated 3.98% — and 2024, when it jumped 70.24%.
• Kiniksa Pharmaceuticals International's Operating Expenses stood at $55.8 million in 2022, then jumped by 49.21% to $83.3 million in 2023, then surged by 70.24% to $141.8 million in 2024, then rose by 28.57% to $182.4 million in 2025, then grew by 1.45% to $185.0 million in 2026.
• The last three Operating Expenses figures came in at $185.0 million (Q1 2026), $182.4 million (Q4 2025), and $156.8 million (Q3 2025), per Business Quant data.